Bulk Manufacturer of Controlled Substances Application: S&B Pharma LLC DBA Norac Pharma, 55985-55986 [2024-14910]
Download as PDF
<![CDATA[
55985
Federal Register / Vol. 89, No. 130 / Monday, July 8, 2024 / Notices
about the changes, as required by 41
CFR 102–3.150(a).
Notice of Federal Advisory
Committee meeting; amended.
ACTION:
Dated: July 3, 2024.
Thomas V. Curtin, Jr.,
Executive Director, Joint Board for the
Enrollment of Actuaries.
This notice amends the
location of the partially closed meeting
of the Advisory Committee on Actuarial
Examinations previously announced in
the Federal Register of June 14, 2024.
SUMMARY:
[FR Doc. 2024–14991 Filed 7–5–24; 8:45 am]
BILLING CODE 4830–01–P
July 11, 2024, from 9 a.m. to 5
p.m., and July 12, 2024, from 9:30 a.m.
to 3 p.m.
DATES:
DEPARTMENT OF JUSTICE
FOR FURTHER INFORMATION CONTACT:
Elizabeth Van Osten, Designated Federal
Officer, Advisory Committee on
Actuarial Examinations, at (202) 312–
3648 or Elizabeth.jvanosten@irs.gov.
As
published in the Federal Register of
June 14, 2024 (89 FR 50634), the
meeting was to be held at the Internal
Revenue Service, 1111 Constitution
Avenue NW, Washington, DC 20224.
However, due to an unexpected
building closure precluding an inperson meeting, the meeting will be
held by teleconference instead. There
are no other changes to the meeting.
Because the circumstances necessitating
the change to the venue of the meeting
are beyond the control of the Joint Board
or the Enrollment of Actuaries, it is
unable to provide public notification
SUPPLEMENTARY INFORMATION:
Drug Enforcement Administration
[Docket No. DEA–1389]
Bulk Manufacturer of Controlled
Substances Application: Curia
Missouri Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Curia Missouri Inc. has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
SUMMARY:
the issuance of the proposed registration
on or before September 6, 2024. Such
persons may also file a written request
for a hearing on the application on or
before September 6, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on May 29, 2024, Curia
Missouri Inc., 2460 West Bennett Street,
Springfield, Missouri 65807–1229,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
Controlled substance
Drug code
Gamma Hydroxybutyric Acid .........................................................................................................................................
Amphetamine .................................................................................................................................................................
Lisdexamfetamine ..........................................................................................................................................................
Methylphenidate .............................................................................................................................................................
Phenylacetone ...............................................................................................................................................................
Tapentadol .....................................................................................................................................................................
The company plans to bulk
manufacture the listed controlled
substances for internal use
intermediates or for sale to its
customers. No other activities for these
drug codes are authorized for this
registration.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–14926 Filed 7–5–24; 8:45 am]
BILLING CODE P
khammond on DSKJM1Z7X2PROD with NOTICES
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1385]
Bulk Manufacturer of Controlled
Substances Application: S&B Pharma
LLC DBA Norac Pharma
Drug Enforcement
Administration, Justice.
AGENCY:
VerDate Sep<11>2014
16:22 Jul 05, 2024
Jkt 262001
ACTION:
Notice of application.
S&B Pharma LLC DBA Norac
Pharma has applied to be registered as
a bulk manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before September 6, 2024. Such
persons may also file a written request
for a hearing on the application on or
before September 6, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
SUMMARY:
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
2010
1100
1205
1724
8501
9780
Schedule
I
II
II
II
II
II
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
In
accordance with 21 CFR 1301.33(a), this
is notice that on April 30, 2024, S&B
Pharma LLC DBA Norac Pharma, 405
South Motor Avenue, Azusa, California
91702, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
E:\FR\FM\08JYN1.SGM
08JYN1
55986
Federal Register / Vol. 89, No. 130 / Monday, July 8, 2024 / Notices
Controlled substance
Drug code
Gamma Hydroxybutyric Acid .........................................................................................................................................
The company plans to manufacture
the above listed controlled substance for
internal research and for development
purposes as part of the process in
seeking Food and Drug Administration
approval prior to distribution to
customers. No other activity for this
drug code is authorized for this
registration.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–14910 Filed 7–5–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1388]
Importer of Controlled Substances
Application: Arizona Department of
Corrections
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
khammond on DSKJM1Z7X2PROD with NOTICES
AGENCY:
Arizona Department of
Corrections has applied to be registered
as an importer of basic class(es) of
controlled substance(s). Refer to
Supplementary Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before August 7, 2024. Such
persons may also file a written request
for a hearing on the application on or
before August 7, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
SUMMARY:
2010
In
accordance with 21 CFR 1301.34(a), this
is notice that on June 3, 2024, Arizona
Department of Corrections, 1305 East
Butte Avenue, ASPC-Florence, Florence,
Arizona 85132–9221, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Drug code
Pentobarbital ........................................................................................................................................................................
2270
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–14918 Filed 7–5–24; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
16:22 Jul 05, 2024
Jkt 262001
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed
Consent Decree Under the Clean Air
Act
On July 1, 2024, the Department of
Justice lodged a proposed consent
decree with the United States District
Court for the Southern District of New
York in the lawsuit entitled United
States v. Gristede’s Foods NY, Inc., Civil
Action No. 24 Civ. 4981.
The United States filed this lawsuit
seeking injunctive relief and civil
penalties for violations of the Clean Air
Act against defendant Gristede’s Foods
NY, Inc. (‘‘Gristedes’’) for violations of
the United States Environmental
Protection Agency’s (‘‘EPA’’) Recycling
and Emissions Reduction Rule, 40 CFR
part 82, subpart F, for failing to take
actions necessary to monitor, prevent,
leak, and record refrigerant emissions.
The consent decree requires Gristedes
to implement a new Refrigerant
Compliance Management Plan; to
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
I
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
Controlled substance
The facility intends to import the
above-listed controlled substance for
legitimate needs. This particular
controlled substance is not available for
the intended legitimate need within the
current domestic supply of the United
States. No other activities for these drug
codes are authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Schedule
Schedule
II
reduce its company-wide refrigerant
leak rates; to repair or replace specified
appliances; to convert certain stores to
using more advanced refrigerants; and
to pay a $400,000 civil penalty to the
United States.
The publication of this notice opens
a period for public comment on the
consent decree. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and should refer to
United States v. Gristede’s Foods NY,
Inc., D.J. Ref. No. 90–5–2–1–12759. All
comments must be submitted no later
than thirty (30) days after the
publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit
comments:
By email .......
E:\FR\FM\08JYN1.SGM
08JYN1
Send them to:
pubcomment-ees.enrd@
usdoj.gov.
]]>Agencies
[Federal Register Volume 89, Number 130 (Monday, July 8, 2024)]
[Notices]
[Pages 55985-55986]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-14910]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1385]
Bulk Manufacturer of Controlled Substances Application: S&B
Pharma LLC DBA Norac Pharma
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: S&B Pharma LLC DBA Norac Pharma has applied to be registered
as a bulk manufacturer of basic class(es) of controlled substance(s).
Refer to Supplementary Information listed below for further drug
information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
September 6, 2024. Such persons may also file a written request for a
hearing on the application on or before September 6, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on April 30, 2024, S&B Pharma LLC DBA Norac Pharma, 405
South Motor Avenue, Azusa, California 91702, applied to be registered
as a bulk manufacturer of the following basic class(es) of controlled
substance(s):
[[Page 55986]]
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid........... 2010 I
------------------------------------------------------------------------
The company plans to manufacture the above listed controlled
substance for internal research and for development purposes as part of
the process in seeking Food and Drug Administration approval prior to
distribution to customers. No other activity for this drug code is
authorized for this registration.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-14910 Filed 7-5-24; 8:45 am]
BILLING CODE P
